Antibody persistence at 1 and 4 years following a single dose of MenAfriVac or Quadrivalent polysaccharide vaccine in healthy subjects aged 2-29 years

Aldiouma Diallo, Samba O. Sow, Olubukola T. Idoko, Siddhivinayak Hirve, Helen Findlow, Marie Pierre Preziosi, Cheryl Elie, Prasad S. Kulkarni, Varsha Parulekar, Bou Diarra, Fadima Cheick Haidara, Fatoumata Diallo, Milagritos Tapia, Adebayo K. Akinsola, Richard A. Adegbola, Ashish Bavdekar, Sanjay Juvekar, Julie Chaumont, Lionel Martellet, Elisa MarchettiMarc F. La Force, Brian D. Plikaytis, Godwin C. Enwere, Yuxiao Tang, Raymond Borrow, George Carlone, Simonetta Viviani*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Background. Mass vaccination campaigns of the population aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in India and found to be safe and highly immunogenic compared with the group A component of the licensed quadrivalent polysaccharide vaccine (PsACWY). Antibody persistence in Africa and in India was investigated. Methods. A total of 900 subjects aged 2-29 years were followed up for 4 years in Senegal, Mali, and The Gambia (study A). A total of 340 subjects aged 2-10 years were followed up for 1 year in India (study B). In study A, subjects were randomized in a 2:1 ratio, and in study B a 1:1 ratio to receive either PsA-TT or PsACWY. Immunogenicity was evaluated by measuring MenA serum bactericidal antibody (SBA) with rabbit complement and by a group A-specific immunoglobulin G (IgG) enzyme-linked immunosorbent assay. Results. In both studies, substantial SBA decay was observed at 6 months postvaccination in both vaccine groups, although more marked in the PsACWY group. At 1 year and 4 years (only for study A) postvaccination, SBA titers were relatively sustained in the PsA-TT group, whereas a slight increasing trend, more pronounced among the youngest, was observed in the participants aged <18 years in the PsACWY groups. The SBA titers were significantly higher in the PsA-TT group than in the PsACWY group at any time point, and the majority of subjects in the PsA-TT group had SBA titers ≥128 and group A-specific IgG concentrations ≥2 μg/mL at any point in time in both the African and Indian study populations. Conclusions. Four years after vaccination with a single dose of PsA-TT vaccine in Africa, most subjects are considered protected from MenA disease.

Original languageEnglish
Pages (from-to)S521-S530
JournalClinical Infectious Diseases
Publication statusPublished - 15 Nov 2015

Bibliographical note

Publisher Copyright:
© 2015 The Author. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.


  • African meningitis belt
  • India
  • MenA conjugate vaccine
  • antibody persistence


Dive into the research topics of 'Antibody persistence at 1 and 4 years following a single dose of MenAfriVac or Quadrivalent polysaccharide vaccine in healthy subjects aged 2-29 years'. Together they form a unique fingerprint.

Cite this